John A Stalfort III's Net Worth
$19.6 Million
Who is John A Stalfort III?
John A Stalfort III has an estimated net worth of $19.6 Million. This is based on reported shares across multiple companies, which include Verrica Pharmaceuticals Inc., Acumen Pharmaceuticals, Inc., Dova Pharmaceuticals, Inc., and Taysha Gene Therapies, Inc..
SEC CIK
John A Stalfort III's CIK is 0001709418
Past Insider Trading and Trends
2023 was John A Stalfort III's most active year for acquiring shares with 4 total transactions. John A Stalfort III's most active month to acquire stocks was the month of May. 2018 was John A Stalfort III's most active year for disposing of shares, totalling 1 transactions. John A Stalfort III's most active month to dispose stocks was the month of May. 2021 saw John A Stalfort III paying a total of $560,000.00 for 199,180 shares, this is the most they've acquired in one year. In 2019 John A Stalfort III cashed out on 635,665 shares for a total of $17,480,787.50, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Verrica Pharmaceuticals Inc. (VRCA) Snapshot price: $1.9099
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +51.52% | 238.09K |
$2.10 | $499,999.50 | 700.21K |
Jul 5
| |||
Form 4
| +7.25% | 31.25K |
$6.41 | $200,463.50 | 462.11K |
Aug 13 - Aug 14
| |||
Form 4
| +2.19% | 9.22K |
$10.45 | $96,385.98 | 430.86K |
Jan 7
| |||
Form 4
| +1,441.98% | 394.3K |
—
|
—
| 421.64K |
Jun 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Acumen Pharmaceuticals, Inc. (ABOS) Snapshot price: $2.18
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
| +4,154.19% | 296.77K |
$16.00 |
—
| 303.92K |
Jul 6
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Dova Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -635.66K |
$27.50 | -$17,480,787.50 |
0
|
Nov 12
| |||
Form 4
| +5.13% | 31K |
$6.26 | $194,060.00 | 635.66K |
Dec 20
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Taysha Gene Therapies, Inc. (TSHA) Snapshot price: $2.09
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +4.69% | 49.22K |
—
|
—
| 1.1M |
May 29
| |||
Form 4
| +74.85% | 827.78K |
$0.90 | $700,000.20 | 1.93M |
Aug 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||